Shopping Cart
- Remove All
Your shopping cart is currently empty
VRT-532 (CFpot-532) is an effective modulator of CFTR and is commonly used in studies of cystic fibrosis (CF) caused by CFTR defects. Modification of CFTR by this small molecule modulator can increase arylsulfatase B (ARSB), which is necessary to reduce the accumulation of sulphate glycosaminosaccharide (gag), thus reducing the accumulation of 4-chondroitin sulfate in cystic fibrosis.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $67 | In Stock | |
| 5 mg | $167 | In Stock | |
| 10 mg | $251 | In Stock | |
| 25 mg | $413 | In Stock | |
| 50 mg | $559 | In Stock | |
| 100 mg | $735 | In Stock | |
| 200 mg | $973 | In Stock |
| Description | VRT-532 (CFpot-532) is an effective modulator of CFTR and is commonly used in studies of cystic fibrosis (CF) caused by CFTR defects. Modification of CFTR by this small molecule modulator can increase arylsulfatase B (ARSB), which is necessary to reduce the accumulation of sulphate glycosaminosaccharide (gag), thus reducing the accumulation of 4-chondroitin sulfate in cystic fibrosis. |
| In vitro | VRT-532 binds directly to G551D-CFTR in isolated systems, thereby improving its channel function and increasing its ATPase rate. VRT-325 decreased the apparent ATP affinity of purified and reconstituted F508del-CFTR[1]. |
| Synonyms | CFpot-532, CFpot532 |
| Molecular Weight | 250.3 |
| Formula | C16H14N2O |
| Cas No. | 38214-71-0 |
| Smiles | CC1=CC=C(O)C(=C1)C1=NNC(=C1)C1=CC=CC=C1 |
| Relative Density. | 1.213 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||
| Solubility Information | DMSO: 2.5 mg/mL (9.99 mM), Sonication is recommended. | |||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (4 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||
Solution Preparation Table | ||||||||||||||||
DMSO
| ||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.